Mary Rozenman

Mary Rozenman is insitro’s CFO/CBO and has been with the company since 2019. At insitro, Mary leads strategic and operational functions, including finance and accounting, strategy, business development, investor relations and corporate communications. Mary serves as an independent director on the board of Tessera Therapeutics, a company pioneering gene writing. Mary has been recognized on Endpoints’ top 20 under 40 in biopharma list and the Business Insider top 30 under 40 transforming healthcare.

Prior to insitro, she was SVP of corporate development and strategy at Aimmune Therapeutics (acquired by Nestlé Health Sciences for $2.6B), where she was a founding team member and led collaborations with companies including Regeneron, Sanofi and Nestlé. Mary has raised over $1B in capital through a range of private and public transactions, including co-leading Aimmune’s 2015 IPO. Before Aimmune, Mary was a biotechnology investor at Longitude Capital and a junior partner at McKinsey & Company focused on pharmaceuticals and corporate finance.

Mary holds a Ph.D. in organic chemistry and chemical biology from Harvard University, where she worked with David R. Liu, and a B.A. in biochemistry and Russian literature from Columbia University where she was a John Jay Scholar. Her academic work has been published in premier journals including Nature, and she is a named inventor on several patents. In her free time, Mary enjoys cooking, travel, golf, and spending time with her husband and two children.